SAN DIEGO--(BUSINESS WIRE)--Aug. 3, 2018--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem”), a medical device
company and manufacturer of the only touchscreen insulin pumps available
in the United States, today announced the pricing of an underwritten
public offering of 3,508,770 shares of its common stock at a price to
the public of $28.50 per share. The gross proceeds to Tandem from this
offering are expected to be approximately $100.0 million, before
deducting underwriting discounts and commissions and other estimated
offering expenses payable by Tandem. In addition, Tandem has granted the
underwriters a 30-day option to purchase up to 526,315 additional shares
of its common stock. All of the shares of common stock to be sold in the
offering are being offered by Tandem. The offering is expected to close
on or about August 7, 2018, subject to the satisfaction of customary
Oppenheimer & Co. Inc. is acting as the sole book‐running manager for
the offering. Robert W. Baird & Co. Incorporated is acting as a
co-manager in connection with the offering.
This offering is being made pursuant to a shelf registration statement
on Form S-3 that was filed by Tandem with the Securities and Exchange
Commission (SEC) and declared effective on May 9, 2018. A preliminary
prospectus supplement and accompanying prospectus describing the terms
of the proposed offering has been filed with the SEC and will form a
part of the effective registration statement and a final prospectus
supplement will be filed with the SEC. When available, copies of the
final prospectus supplement and the accompanying prospectus relating to
the securities being offered may be obtained from: Oppenheimer & Co.
Inc. Attention: Syndicate Prospectus Department, 85 Broad St., 26th
Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com.
Electronic copies of the final prospectus supplement and accompanying
prospectus will also be available on the Securities and Exchange
Commission’s website at www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any
such state or jurisdiction. The offering will be made only by means of a
prospectus that forms a part of the registration statement.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. Tandem takes an innovative, user-centric approach to the
design, development and commercialization of products for people with
diabetes who use insulin. Tandem manufactures and sells the t:slim X2™
Insulin Pump with Basal-IQ™ technology. The t:slim X2 Pump is capable of
remote feature updates using a personal computer, and is the first
insulin pump designated as compatible with integrated continuous glucose
monitoring (iCGM) devices. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark, and t:slim X2 and
Basal-IQ are trademarks of Tandem Diabetes Care, Inc.
Forward Looking Statements
This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
include statements regarding the closing of the public offering, the
anticipated proceeds from the offering and other statements that are not
purely statements of historical fact. Such forward-looking statements
are based on Tandem's current expectations and involve assumptions that
may never materialize or may prove to be incorrect. Actual results, and
the timing of events, may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including the uncertainties regarding Tandem's ability to satisfy
closing conditions related to the proposed offering. Other risks and
uncertainties are identified in Tandem’s most recent Annual Report on
Form 10-K and Quarterly Report on Form 10-Q, and other documents that
Tandem files with the Securities and Exchange Commission including the
Registration Statement on Form S-3 for the offering. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. Unless
otherwise required by applicable law or the rules of the NASDAQ Stock
Market, Tandem undertakes no obligation to update or revise any
forward-looking statement in this press release because of new
information, future events or other factors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180803005262/en/
Source: Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc.
Susan Morrison, 858-366-6900 x7005